We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · January 25, 2021

Single or Combined ICIs vs First-Line Platinum-Based Chemotherapy ± Bevacizumab in Advanced NSCLC

The Cochrane Database of Systematic Reviews

 

Additional Info

The Cochrane Database of Systematic Reviews
Single or Combined Immune Checkpoint Inhibitors Compared to First-Line Platinum-Based Chemotherapy With or Without Bevacizumab for People With Advanced Non-Small Cell Lung Cancer
Cochrane Database Syst Rev 2020 Dec 14;[EPub Ahead of Print], R Ferrara, M Imbimbo, R Malouf, S Paget-Bailly, F Calais, C Marchal, V Westeel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading